← Back to Search

Personalized Risk Feedback for Lung Cancer Screening and Smoking Cessation (PRECISE Trial)

N/A

Waitlist Available

Led By Li-Shiun Chen, M.D., MPH, ScD

Research Sponsored by Washington University School of Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Between 50 to 80 years of age, inclusive

Be older than 18 years old

Must not have

Lung cancer diagnosis

Timeline

Screening 3 weeks

Treatment Varies

Follow Up exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years)

Awards & highlights

No Placebo-Only Group

Summary

This trial tests how two versions of a personalized risk feedback tool affect lung cancer screening and tobacco treatment. It looks at how clinicians and patients respond.

Who is the study for?

This trial is for current smokers or those who quit within the last 15 years, aged 50-80, with a history of heavy smoking (≥20 pack-years), and have never been screened for lung cancer. Participants must be patients of clinicians in the study's clinics and speak English. Those already scheduled for lung cancer screening, diagnosed with lung cancer, or unable to provide a DNA sample are excluded.

What is being tested?

The trial examines two personalized risk feedback tools—clinically-informed (RiskProfile-Clin) and genetically-informed (RiskProfile-Gen)—against standard care. It aims to see if these tools affect how often doctors order lung cancer screenings/smoking cessation treatments and if their patients follow through.

What are the potential side effects?

Since this trial involves risk assessment tools rather than medications or medical procedures, there are no direct side effects associated with the interventions being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50 and 80 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have been diagnosed with lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and exit interview [after last patient is enrolled per clinician at the time of the last intervention (approximately 3 years) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Clinician ordering of lung cancer screening

Clinician prescribing of tobacco treatment

Patient completion of lung cancer screening

+6 more

Other study objectives

Patient-centeredness of care discussions regarding screening and treatment (Clinicians)

Patient-centeredness of care discussions regarding screening and treatment (Patients)

Perceived benefits of screening and treatment (Clinicians)

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: RiskProfile-GenExperimental Treatment1 Intervention

RiskProfile-Gen is a genetically-informed risk feedback tool to activate cancer risk-reducing behaviors.

Group II: RiskProfile-ClinExperimental Treatment1 Intervention

RiskProfile-Clin is a clinically-informed risk feedback tool to activate cancer risk-reducing behaviors.

Group III: Usual CareActive Control1 Intervention

Annual lung cancer screening with low-dose computed tomography (LDCT) is currently recommended in the U.S. for at-risk patients. Tobacco treatment and cessation is recommended for patients who smoke.

0 / 2Eligibility criteria met